Lead Optimization of P5U and Urantide: Discovery of Novel Potent Ligands at the Urotensin-II Receptor(672 views) Carotenuto A, Auriemma L, Merlino F, Yousif AM, Marasco D, Limatola A, Campiglia P, Gomez-Monterrey I, Santicioli P, Meini S, Maggi CA, Novellino E, Grieco P
Keywords: Ligand, Unclassified Drug, Upg 100, Urotensin Receptor Antagonist, Animal Tissue, Article, Bioassay, Competitive Inhibition, Controlled Study, Drug Design, Drug Receptor Binding, Drug Stability, Nonhuman, Nuclear Overhauser Effect, Process Optimization, Protein Degradation, Proton Nuclear Magnetic Resonance, Receptor Affinity, Structure Activity Relation, Dose-Response Relationship, Drug Discovery, Models, Molecular, Molecular Conformation, Peptide Fragments, Cyclic, G-Protein-Coupled, Structure-Activity Relationship,
Affiliations: *** IBB - CNR ***
Department of Pharmacy, University of Naples Federico II, I-80131 Naples, Italy
CIRPEB: Centro Interuniversitario di Ricerca sui Peptidi Bioattivi, University of Naples Federico II, Institute of Biostructures and Bioimaging-CNR, Naples, Italy
References: Bern, H.A., Lederis, K., A Reference Preparation for the Study of Active Substances in the Caudal Neurosecretory System of Teleosts (1969) J. Endrocninol., 45 (SUPPL.
Pearson, D., Shively, J.E., Clark, B.R., Geschwind, I.I., Barkley, M., Nishioka, R.S., Bern, H.A., Urotensin II: A Somatostain-like Peptide in the Caudal Neurosecretory System of Fishes (1980) Proc. Natl. Acad. Sci. U.S.A., 77, pp. 5021-5024
Conlon, J.M., O'Harte, F., Smith, D.D., Tonon, M.C., Vaudry, H., Isolation and Primary Structure of Urotensin II from the Brain of a Tetrapod, the Frog Rana ridibunda (1992) Biochem. Biophys. Res. Commun., 188, pp. 578-583
Mori, M., Sugo, T., Abe, M., Shimomura, Y., Kurihara, M., Kitada, C., Kikuchi, K., Fujino, M., Urotensin II is the Endogenous Ligand of a G-protein Coupled Orphan Receptor, SENR (GPR14) (1999) Biochem. Biophys. Res. Commun., 265, pp. 123-129
Nothacker, H.P., Wang, Z., McNeill, A.M., Saito, Y., Merten, S., O'Dowd, B., Duckles, S.P., Civelli, O., Identification of the Natural Ligand of an Orphan G-Protein-Coupled Receptor Involved in the Regulation of Vasoconstriction (1999) Nat. Cell Biol., 1, pp. 383-385
Ames, R.S., Sarau, H.M., Chambers, J.K., Willette, R.N., Aiyar, R.V., Romanic, A.M., Louden, C.S., Douglas, S.A., Human Urotensin-II Is a Potent Vasoconstrictor and Agonist for the Orphan Receptor GPR14 (1999) Nature, 401, pp. 282-286
Vaudry, H., Do Rego, J.C., Le Mevel, J.C., Chatenet, D., Tostivint, H., Fournier, A., Tonon, M.C., Leprince, J., Urotensin II, from Fish to Human (2010) Ann. N.Y. Acad. Sci., 200, pp. 53-66
Sugo, T., Murakami, Y., Shimomura, Y., Harada, M., Abe, M., Ishibashi, Y., Kitada, C., Fujino, M., Identification of Urotensin II-Related Peptide as the Urotensin II Immunoreactive Molecule in the Rat Brain (2003) Biochem. Biophys. Res. Commun., 310, pp. 860-868
Maguire, J.J., Kuc, R.E., Davenport, A.P., Orphan-Receptor Ligand Human Urotensin II: Receptor Localization Human Tissues and Comparison of Vasoconstrictor Responses with Endothelin-1 (2000) Br. J. Pharmacol., 131, pp. 441-446
Maguire, J.J., Davenport, A.P., Is Urotensin-II the New Endothelin? (2002) Br. J. Pharmacol., 137, pp. 579-588
Matsushita, M., Shichiri, M., Imai, T., Iwashina, M., Tanaka, H., Takasu, N., Hirata, Y., Co-Expression of Urotensin II and Its Receptor (GPR14) in Human Cardiovascular and Renal Tissues (2001) J. Hypertens., 19, pp. 2185-2190
Zhu, Y.C., Zhu, Y.Z., Moore, P.K., The Role of Urotensin II in Cardiovascular and Renal Physiology and Diseases (2006) Br. J. Pharmacol., 148, pp. 884-901
Suzuki, S., Wenyi, Z., Hirai, M., Hinokio, Y., Suzuki, C., Yamada, T., Yoshizumi, S., Oka, Y., Genetic Variations at Urotensin II and Urotensin II Receptor Genes and Risk of Type 2 Diabetes Mellitus in Japanese (2004) Peptides, 25, pp. 1803-1808
Douglas, S.A., Ohlstein, E.H., Human Urotensin-II, the Most Potent Mammalian Vasoconstrictor Identified to Date, as a Therapeutic Target for the Management of Cardivascular Diseases (2000) Trends Cardiovasc. Med., 10, pp. 229-237
Papadopoulos, P., Bousette, N., Giaid, A., Urotensin-II and Cardiovascular Remodeling (2008) Peptides, 29, pp. 764-769
Djordjevic, T., Belaiba, R.S., Bonello, S., Pfeilschifter, J., Hess, J., Gorlach, A., Human Urotensin II Is a Novel Activator of NADPH Oxidase in Human Pulmonary Artery Smooth Muscle Cells (2005) Arterioscler. Thromb. Vasc. Biol., 25, pp. 519-525
D'Emmanuele Di Villa Bianca, R., Mitidieri, E., Coletta, C., Grassia, G., Roviezzo, F., Grieco, P., Novellino, E., Sorrentino, R., Urotensin II: A Novel Target in Human Penile Erection (2010) J. Sex. Med., 7, pp. 1178-1186
Grieco, P., Franco, R., Bozzuto, G., Toccacieli, L., Sgambato, A., Marra, M., Zappavigna, S., Caraglia, M., Urotensin II Receptor Predicts the Clinical Outcome of Prostate Cancer Patients and Is Involved in the Regulation of Motility of Prostate Adenocarcinoma Cells (2011) J. Cell Biochem., 112, pp. 341-353
Liang, D.Y., Liu, L.M., Ye, C.G., Zhao, L., Yu, F.P., Gao, D.Y., Wang, Y.Y., Wang, Y.Y., Inhibition of UII/UTR System Relieves Acute Inflammation of Liver through Preventing Activation of NF-κB Pathway in ALF Mice (2013) PLoS One, 8, p. 64895
Matsumoto, Y., Abe, M., Watanabe, T., Adachi, Y., Yano, T., Takahashi, H., Sugo, T., Fujino, M., Intracerebroventricular Administration of Urotensin II Promotes Anxiogenic-like Behaviors in Rodents (2004) Neurosci. Lett., 358, pp. 99-102
Chatenet, D., Nguyen, T.T., Létourneau, M., Fournier, A., Update on the Urotensinergic System: New Trends in Receptor Localization, Activation, and Drug Design (2013) Front Endocrinol., 3, pp. 1-13
Maryanoff, B.E., Kinney, W.A., Urotensin-II Receptor Modulators as Potential Drugs (2010) J. Med. Chem., 53, pp. 2695-2708
Conlon, J.M., Yano, K., Waugh, D., Hazon, N., Distribution and Molecular Forms of Urotensin II and Its Role in Cardiovascular Regulation in Vertebrates (1996) J. Exp. Zool., 275, pp. 226-238
Chatenet, D., Dubessy, C., Leprince, J., Boularan, C., Carlier, L., Segalas-Milazzo, I., Guilhaudis, L., Vaudry, H., Structure-Activity Relationships and Structural Conformation of a Novel Urotensin II-Related Peptide (2004) Peptides, 25, pp. 1819-1830
Flohr, S., Kurz, M., Kostenis, E., Brkovich, A., Fournier, A., Klabunde, T., Identification of Nonpeptidic Urotensin II Receptor Antagonists by Virtual Screening Based on a Pharmacophore Model Derived from Structure-Activity Relationships and Nuclear Magnetic Resonance Studies on Urotensin II (2002) J. Med. Chem., 45, pp. 1799-1805
Kinney, W.A., Almond, H.R., Qi, J., Smith, C.E., Santulli, R.J., De Garavilla, L., Andrade-Gordon, P., Maryanoff, B.E., Structure-Function Analysis of Urotensin II and Its Use in the Construction of a Ligand-Receptor Working Model (2002) Angew. Chem., Int. Ed., 41, pp. 2940-2944
Brkovic, A., Hattenberger, A., Kostenis, E., Klabunde, T., Flohr, S., Kurz, M., Bourgault, S., Fournier, A., Functional and Binding Characterizations of Urotensin II-Related Peptides in Human and Rat Urotensin II-Receptor Assay (2003) J. Pharmacol. Exp. Ther., 306, pp. 1200-1209
Labarrere, P., Chatenet, D., Leprince, J., Marionneau, C., Loirand, G., Tonon, M.C., Dubessy, C., Vaudry, H., Structure-Activity Relationships of Human Urotensin II and Related Analogues on Rat Aortic Ring Contraction (2003) J. Enz. Inhib. Med. Chem., 18, pp. 77-88
Coy, D.H., Rossowski, W.J., Cheng, B.L., Taylor, J.E., Structural Requirements at the N-Terminus of Urotensin II Octapeptides (2002) Peptides, 23, pp. 2259-2264
Grieco, P., Carotenuto, A., Campiglia, P., Zampelli, E., Patacchini, R., Maggi, C.A., Novellino, E., Rovero, P., A New Potent Urotensin-II Receptor Peptide Agonist Containing a Pen Residue at Disulfide Bridge (2002) J. Med. Chem., 45, pp. 4391-4394
Patacchini, R., Santicioli, P., Giuliani, S., Grieco, P., Novellino, E., Rovero, P., Maggi, C.A., Urantide: An Ultrapotent Urotensin II Antagonist Peptide in the Rat Aorta (2003) Br. J. Pharmacol., 140, pp. 1155-1158
Zhao, J., Yu, Q.X., Kong, W., Gao, H.C., Sun, B., Xie, Y.Q., Ren, L.Q., The Urotensin II Receptor Antagonist, Urantide, Protects against Atherosclerosis in Rats (2013) Exp. Ther. Med., 5, pp. 1765-1769
Novellino, E., Grieco, P., Rovero, P., (2005) Cyclic Peptides Acting As Urotensin II Antagonists, and Use in the Treatment of Hypertension and Other Cardiovascular Conditions and in Urotensin II Receptor Characterization, , PCT Int. Appl. WO 2005023845 A2 20050317
Pitaro, M., Chiarella, A., Peptidi Ciclici Sintetici Agonisti Ed Antagonisti dell'Urotensina II e Relative Procedimento di Produzione, , Italian Patent RM2013A000470
Carotenuto, A., Auriemma, L., Merlino, F., Limatola, A., Campiglia, P., Gomez-Monterrey, I., D'Emmanuele Di Villa Bianca, R., Grieco, P., New Insight into the Binding Mode of Peptides at Urotensin-II Receptor by Trp-Constrained Analogues of P5U and Urantide (2013) J. Pept. Sci., 5, pp. 293-300
Fernandez-Lopez, S., Kim, H.S., Choi, E.C., Delgado, M., Granja, J.R., Khasanov, A., Kraehenbuehl, K., Ghadiri, M.R., Antibacterial Agents Based on the Cyclic d, l -Alpha-Peptide Architecture (2001) Nature, 412, pp. 452-455
Erratum (2001) Nature, 414, p. 329
Chan, L.Y., Gunasekera, S., Henriques, S.T., Worth, N.F., Le, S.J., Clark, R.J., Campbell, J.H., Daly, N.L., Engineering Pro-Angiogenic Peptides Using Stable, Disulfide-Rich Cyclic Scaffolds (2011) Blood, 118, pp. 6709-6717
Carotenuto, A., Grieco, P., Campiglia, P., Novellino, E., Rovero, P., Unraveling the Active Conformation of Urotensin II (2004) J. Med. Chem., 47, pp. 1652-1661
Di Cianni, A., Carotenuto, A., Brancaccio, D., Novellino, E., Reubi, J.C., Beetschen, K., Papini, A.M., Ginanneschi, M., Novel Octreotide Dicarba-Analogues with High Affinity and Different Selectivity for Somatostatin Receptors (2010) J. Med. Chem., 53, pp. 6188-6197
Saviello, M.R., Malfi, S., Campiglia, P., Cavalli, A., Grieco, P., Novellino, E., Carotenuto, A., New Insight into the Mechanism of Action of the Antimicrobial Peptides Temporins (2010) Biochemistry, 49, pp. 1477-1485
Wüthrich, K., (1986) NMR of Proteins and Nucleic Acids, , In
John Wiley & Sons: New York
Guerrini, R., Camarda, V., Marzola, E., Arduin, M., Calo, G., Spagnol, M., Rizzi, A., Regoli, D., Structure-Activity Relationship Study on Human Urotensin II (2005) J. Pept. Sci., 2, pp. 85-90
Leprince, J., Chatenet, D., Dubessy, C., Fournier, A., Pfeiffer, B., Scalbert, E., Renard, P., Vaudry, H., Structure-Activity Relationships of Urotensin II and URP (2008) Peptides, 5, pp. 658-673
Batuwangala, M., Camarda, V., McDonald, J., Marzola, E., Lambert, D.G., Ng, L.L., Calò, G., Salvadori, S., (2009) Peptides, 30, pp. 1130-1136
Camarda, V., Song, W., Marzola, E., Spagnol, M., Guerrini, R., Salvatori, S., Regoli, D., Lambert, D.G., Urantide Mimics Urotensin-II Induced Calcium Release in Cells Expressing Recombinant UT Receptors (2004) Eur. J. Pharmacol., 498, pp. 83-86
Chen, Z., Xu, J., Ye, Y., Li, Y., Gong, H., Zhang, G., Wu, J., Zou, Y., Urotensin II Inhibited the Proliferation of Cardiac Side Population Cells in Mice during Pressure Overload by JNK-LRP6 Signalling (2014) J. Cell. Mol. Med., , 10.1111/jcmm.12230
Gao, S., Oh, Y.B., Shah, A., Park, W.H., Chung, M.J., Lee, Y.H., Kim, S.H., Urotensin II Receptor Antagonist Attenuates Monocrotaline-Induced Cardiac Hypertrophy in Rats (2010) Am. J. Physiol. Heart Circ. Physiol., 299, pp. 1782-1789
Zhang, J.Y., Chen, Z.W., Yao, H., Protective Effect of Urantide Against Ischemia-Reperfusion Injury via Protein Kinase C and Phosphtidylinositol 3′-Kinase-Akt Pathway (2012) Can. J. Physiol. Pharmacol., 90, pp. 637-645
Brancaccio, D., Limatola, A., Campiglia, P., Gomez-Monterrey, I., Novellino, E., Grieco, P., Carotenuto, A., Urantide Conformation and Interaction with Urotensin-II Receptor (2013) Arch. Pharm., 246, pp. 1-8
Wang, S.S., Tam, J.P., Wang, B.S., Merrifield, R.B., Enhancement of Peptide Coupling Reactions by 4-Dimethylaminopyridine (1981) Int. J. Pept. Protein Res., 18, pp. 459-467
Atherton, E., Sheppard, R.C., (1989) Solid-Phase Peptide Synthesis: A Practical Approach, , IRL Press: Oxford, U.K
Misika, A., Hruby, V.J., Optimization of Disulfide Bond Formation (1994) Polym. J. Chem., 68, pp. 893-899
Kenakin, T., Orthosteric Drug Antagonism (2006) A Pharmacology Primer: Theory, Application, and Methods, p. 99. , In, 2 nd ed. Elsevier, Academic Press: London, UK - 126
Arunlakshana, O., Schild, H.O., Some Quantitative Uses of Drug Antagonists (1959) Br. J. Pharmacol. Chemother., 14, pp. 48-58
Cheng, Y., Prusoff, W.H., Relationship between the Inhibition Constant (Ki) and the Concentration of Inhibitor which Causes 50 per Cent Inhibition (I50) of an Enzymatic Reaction (1973) Biochem. Pharmacol., 22, pp. 3099-3108
Riddy, D.M., Stamp, C., Sykes, D.A., Charlton, S.J., Dowling, M.R., Reassessment of the Pharmacology of Sphingosine-1-phosphate S1P3 Receptor Ligands Using the DiscoveRx PathHunter and Ca2+ Release Functional Assays (2012) Br. J. Pharmacol., 167, pp. 868-880
Nguyen, L.T., Chau, J.K., Perry, N.A., De Boer, L., Zaat, S.A., Vogel, H.J., Serum Stabilities of Short Tryptophan- and Arginine-Rich Antimicrobial Peptide Analogs (2010) PLoS One, 5, p. 12684
Doti, N., Scognamiglio, P.L., Madonna, S., Scarponi, C., Ruvo, M., Perretta, G., Albanesi, C., Marasco, D., New Mimetic Peptides of the Kinase-Inhibitory Region (KIR) of SOCS1 through Focused Peptide Libraries (2012) Biochem. J., 443, pp. 231-240
Hwang, T.L., Shaka, A.J., Water Suppression That Works. Excitation Sculpting Using Arbitrary Wave-Forms and Pulsed-Field Gradients (1995) J. Magn. Reson., 112, pp. 275-279
Piantini, U., Sorensen, O.W., Ernst, R.R., Multiple Quantum Filters for Elucidating NMR Coupling Network (1982) J. Am. Chem. Soc., 104, pp. 6800-6801
Marion, D., Wüthrich, K., Application of Phase Sensitive Two-Dimensional Correlated Spectroscopy (COSY) for Measurements of 1H-1H Spin-Spin Coupling Constants in Proteins (1983) Biochem. Biophys. Res. Commun., 113, pp. 967-974
Braunschweiler, L., Ernst, R.R., Coherence Transfer by Isotropic Mixing: Application to Proton Correlation Spectroscopy (1983) J. Magn. Reson., 53, pp. 521-528
Jenner, J., Meyer, B.H., Bachman, P., Ernst, R.R., Investigation of Exchange Processes by Two-Dimensional NMR Spectroscopy (1979) J. Chem. Phys., 71, pp. 4546-4553
States, D.J., Haberkorn, R.A., Ruben, D.J., A Two-Dimensional Nuclear Overhauser Experiment with Pure Absorption Phase in Four Quadrants (1982) J. Magn. Reson., 48, pp. 286-292
Bartels, C., Xia, T., Billeter, M., Guentert, P., Wüthrich, K., The Program XEASY for Computer-Supported NMR Spectral Analysis of Biological Macromolecules (1995) J. Biomol. NMR, 6, pp. 1-10
Güntert, P., Mumenthaler, C., Wüthrich, K., Torsion Angle Dynamics for NMR Structure Calculation with the New Program DYANA (1997) J. Mol. Biol., 273, pp. 283-298
Koradi, R., Billeter, M., Wüthrich, K., MOLMOL: A Program for Display and Analysis of Macromolecular Structures (1996) J. Mol. Graphics, 14, pp. 51-55
Maple, J., Dinur, U., Hagler, A.T., Derivation of Force Fields for Molecular Mechanics and Dynamics from Ab Initio Energy Surface (1988) Proc. Natl. Acad. Sci. U. S. A., 85, pp. 5350-5354
Bern, H. A., Lederis, K., A Reference Preparation for the Study of Active Substances in the Caudal Neurosecretory System of Teleosts (1969) J. Endrocninol., 45 (SUPPL.
Conlon, J. M., O'Harte, F., Smith, D. D., Tonon, M. C., Vaudry, H., Isolation and Primary Structure of Urotensin II from the Brain of a Tetrapod, the Frog Rana ridibunda (1992) Biochem. Biophys. Res. Commun., 188, pp. 578-583
Nothacker, H. P., Wang, Z., McNeill, A. M., Saito, Y., Merten, S., O'Dowd, B., Duckles, S. P., Civelli, O., Identification of the Natural Ligand of an Orphan G-Protein-Coupled Receptor Involved in the Regulation of Vasoconstriction (1999) Nat. Cell Biol., 1, pp. 383-385
Ames, R. S., Sarau, H. M., Chambers, J. K., Willette, R. N., Aiyar, R. V., Romanic, A. M., Louden, C. S., Douglas, S. A., Human Urotensin-II Is a Potent Vasoconstrictor and Agonist for the Orphan Receptor GPR14 (1999) Nature, 401, pp. 282-286
Maguire, J. J., Kuc, R. E., Davenport, A. P., Orphan-Receptor Ligand Human Urotensin II: Receptor Localization Human Tissues and Comparison of Vasoconstrictor Responses with Endothelin-1 (2000) Br. J. Pharmacol., 131, pp. 441-446
Maguire, J. J., Davenport, A. P., Is Urotensin-II the New Endothelin? (2002) Br. J. Pharmacol., 137, pp. 579-588
Zhu, Y. C., Zhu, Y. Z., Moore, P. K., The Role of Urotensin II in Cardiovascular and Renal Physiology and Diseases (2006) Br. J. Pharmacol., 148, pp. 884-901
Douglas, S. A., Ohlstein, E. H., Human Urotensin-II, the Most Potent Mammalian Vasoconstrictor Identified to Date, as a Therapeutic Target for the Management of Cardivascular Diseases (2000) Trends Cardiovasc. Med., 10, pp. 229-237
Liang, D. Y., Liu, L. M., Ye, C. G., Zhao, L., Yu, F. P., Gao, D. Y., Wang, Y. Y., Wang, Y. Y., Inhibition of UII/UTR System Relieves Acute Inflammation of Liver through Preventing Activation of NF- B Pathway in ALF Mice (2013) PLoS One, 8, p. 64895
Maryanoff, B. E., Kinney, W. A., Urotensin-II Receptor Modulators as Potential Drugs (2010) J. Med. Chem., 53, pp. 2695-2708
Conlon, J. M., Yano, K., Waugh, D., Hazon, N., Distribution and Molecular Forms of Urotensin II and Its Role in Cardiovascular Regulation in Vertebrates (1996) J. Exp. Zool., 275, pp. 226-238
Kinney, W. A., Almond, H. R., Qi, J., Smith, C. E., Santulli, R. J., De Garavilla, L., Andrade-Gordon, P., Maryanoff, B. E., Structure-Function Analysis of Urotensin II and Its Use in the Construction of a Ligand-Receptor Working Model (2002) Angew. Chem., Int. Ed., 41, pp. 2940-2944
Coy, D. H., Rossowski, W. J., Cheng, B. L., Taylor, J. E., Structural Requirements at the N-Terminus of Urotensin II Octapeptides (2002) Peptides, 23, pp. 2259-2264
Zhao, J., Yu, Q. X., Kong, W., Gao, H. C., Sun, B., Xie, Y. Q., Ren, L. Q., The Urotensin II Receptor Antagonist, Urantide, Protects against Atherosclerosis in Rats (2013) Exp. Ther. Med., 5, pp. 1765-1769
Chan, L. Y., Gunasekera, S., Henriques, S. T., Worth, N. F., Le, S. J., Clark, R. J., Campbell, J. H., Daly, N. L., Engineering Pro-Angiogenic Peptides Using Stable, Disulfide-Rich Cyclic Scaffolds (2011) Blood, 118, pp. 6709-6717
Saviello, M. R., Malfi, S., Campiglia, P., Cavalli, A., Grieco, P., Novellino, E., Carotenuto, A., New Insight into the Mechanism of Action of the Antimicrobial Peptides Temporins (2010) Biochemistry, 49, pp. 1477-1485
W thrich, K., (1986) NMR of Proteins and Nucleic Acids, , In
Gao, S., Oh, Y. B., Shah, A., Park, W. H., Chung, M. J., Lee, Y. H., Kim, S. H., Urotensin II Receptor Antagonist Attenuates Monocrotaline-Induced Cardiac Hypertrophy in Rats (2010) Am. J. Physiol. Heart Circ. Physiol., 299, pp. 1782-1789
Zhang, J. Y., Chen, Z. W., Yao, H., Protective Effect of Urantide Against Ischemia-Reperfusion Injury via Protein Kinase C and Phosphtidylinositol 3 -Kinase-Akt Pathway (2012) Can. J. Physiol. Pharmacol., 90, pp. 637-645
Stewart, J. M., Young, J. D., (1984) Solid Phase Peptide Synthesis, , In
Wang, S. S., Tam, J. P., Wang, B. S., Merrifield, R. B., Enhancement of Peptide Coupling Reactions by 4-Dimethylaminopyridine (1981) Int. J. Pept. Protein Res., 18, pp. 459-467
Riddy, D. M., Stamp, C., Sykes, D. A., Charlton, S. J., Dowling, M. R., Reassessment of the Pharmacology of Sphingosine-1-phosphate S1P3 Receptor Ligands Using the DiscoveRx PathHunter and Ca2+ Release Functional Assays (2012) Br. J. Pharmacol., 167, pp. 868-880
Nguyen, L. T., Chau, J. K., Perry, N. A., De Boer, L., Zaat, S. A., Vogel, H. J., Serum Stabilities of Short Tryptophan- and Arginine-Rich Antimicrobial Peptide Analogs (2010) PLoS One, 5, p. 12684
Hwang, T. L., Shaka, A. J., Water Suppression That Works. Excitation Sculpting Using Arbitrary Wave-Forms and Pulsed-Field Gradients (1995) J. Magn. Reson., 112, pp. 275-279
Marion, D., W thrich, K., Application of Phase Sensitive Two-Dimensional Correlated Spectroscopy (COSY) for Measurements of 1H-1H Spin-Spin Coupling Constants in Proteins (1983) Biochem. Biophys. Res. Commun., 113, pp. 967-974
States, D. J., Haberkorn, R. A., Ruben, D. J., A Two-Dimensional Nuclear Overhauser Experiment with Pure Absorption Phase in Four Quadrants (1982) J. Magn. Reson., 48, pp. 286-292
G ntert, P., Mumenthaler, C., W thrich, K., Torsion Angle Dynamics for NMR Structure Calculation with the New Program DYANA (1997) J. Mol. Biol., 273, pp. 283-298
Lead Optimization of P5U and Urantide: Discovery of Novel Potent Ligands at the Urotensin-II Receptor
We have optimized 1 (P5U) and urantide, two important ligands at the h-UT receptor, designing several analogues by the exchange of the Tyr(9) residue with different unnatural aromatic amino acids. This study allowed us to discover novel ligands with improved activity. In particular, the replacement of the Tyr(9) residue by (pCN)Phe or (pNO(2))Phe within the urantide sequence led to compounds 13 (UPG-83) and 15 (UPG-95), respectively, which showed pure antagonist activity toward UT receptor in a rat aorta bioassay. More interestingly, the replacement of the Tyr(9) in 1 sequence with the Btz or the (3,4-Cl)Phe residues led to superagonists 6 (UPG-100) and 10 (UPG-92) with pEC(50) values at least 1.4 log higher than that of 1, being the most potent UT agonists discovered to date. Compounds 10 and 13 showed also a good stability in a serum proteolytic assay. These ligands represent new useful tools to further characterize the urotensinergic system in human physiopathology.
Lead Optimization of P5U and Urantide: Discovery of Novel Potent Ligands at the Urotensin-II Receptor
No results.
Lead Optimization of P5U and Urantide: Discovery of Novel Potent Ligands at the Urotensin-II Receptor
Petraglia F, Singh AA, Carafa V, Nebbioso A, Conte M, Scisciola L, Valente S, Baldi A, Mandoli A, Petrizzi VB, Ingenito C, De Falco S, Cicatiello V, Apicella I, Janssen-megens EM, Kim B, Yi G, Logie C, Heath S, Ruvo M, Wierenga ATJ, Flicek P, Yaspo ML, Della Valle V, Bernard O, Tomassi S, Novellino E, Feoli A, Sbardella G, Gut I, Vellenga E, Stunnenberg HG, Mai A, Martens JHA, Altucci L * Combined HAT/EZH2 modulation leads to cancer-selective cell death(284 views) Oncotarget (ISSN: 1949-2553electronic, 1949-2553linking), 2018 May 22; 9(39): 25630-25646. Impact Factor:5.008 ViewExport to BibTeXExport to EndNote
Santulli G, Cipolletta E, Sorriento D, Del Giudice C, Anastasio A, Monaco S, Maione AS, Condorelli G, Puca A, Trimarco B, Illario M, Iaccarino G * CaMK4 gene deletion induces hypertension(349 views) J Am Heart Assoc Journal Of The American Heart Association (ISSN: 2047-9980), 2012; 1(4): N/D-N/D. Impact Factor:2.882 ViewExport to BibTeXExport to EndNote
Bruni AC, Bernardi L, Colao R, Rubino E, Smirne N, Frangipane F, Terni B, Curcio SA, Mirabelli M, Clodomiro A, Di Lorenzo R, Maletta R, Anfossi M, Gallo M, Geracitano S, Tomaino C, Muraca MG, Leotta A, Lio SG, Pinessi L, Rainero I, Sorbi S, Nee L, Milan G, Pappata S, Postiglione A, Abbamondi N, Forloni G, St George Hyslop P, Rogaeva E, Bugiani O, Giaccone G, Foncin JF, Spillantini MG, Puccio G * Worldwide distribution of PSEN1 Met146Leu mutation: A large variability for a founder mutation(849 views) Neurology (ISSN: 0028-3878, 1526-632x, 1526-632xelectronic), 2010 Mar 9; 74(10): 798-806. Impact Factor:8.017 ViewExport to BibTeXExport to EndNote
Aloj L, Aurilio M, Rinaldi V, D'Ambrosio L, Tesauro D, Peitl PK, Maina T, Mansi R, Von Guggenberg E, Joosten L, Sosabowski JK, Breeman WA, De Blois E, Koelewijn S, Melis M, Waser B, Beetschen K, Reubi JC, De Jong M * The EEE project(449 views) Proc Int Cosm Ray Conf Icrc Universidad Nacional Autonoma De Mexico, 2007; 5(HEPART2): 977-980. Impact Factor:0 ViewExport to BibTeXExport to EndNote